Where there’s cancer, there are oncology nurses. It’s been that way even before 1971, when President Richard Nixon established and signed into law the National Cancer Act to fight the “war on cancer,” which had just become the second leading cause of death in the United States. Born from the act, the National Cancer Institute (NCI) celebrates its 50th anniversary in 2021.
As a nurse, you have a diverse arsenal of skills, from clinical competencies and leadership to problem-solving and interprofessional communication. That skillset easily transfers to a variety of careers outside of direct care.
Cancer mortality for all racial and ethnic groups in the United States continues to decline, with death rates for lung cancer and melanoma decreasing faster than others, according to findings that the American Cancer Society (ACS), the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries (NAACCR) published in their July 2021 Annual Report to the Nation on the status of cancer.
The COVID-19 coronavirus pandemic was a wake-up call for preparedness: it caught society unaware and highlighted gaps in virtually every modern-day system. With those lessons learned, when the United States started removing pandemic-related public health restrictions and we began a return to “normal,” experts from all corners of society started looking to what the future will bring.
On July 26, 2021, the American Nurses Association (ANA) signed onto a statement released by a large group of healthcare systems and other associations in support of healthcare employers mandating nurses and all healthcare personnel be vaccinated against the COVID-19 coronavirus. This is in response to increasing circulation of COVID-19 variants and lagging vaccination rates.
Oncology nurses have a responsibility to continually enhance their career and practice—for their patients, for their profession, and even for themselves. Two strategies for doing that are certification and mentorship. Combining the two is an even more powerful approach.
On July 28, 2021, the U.S. Food and Drug Administration (FDA) reported that a clinical trial (OCEAN, Study OP-103) evaluating melphalan flufenamide (Pepaxto®) with dexamethasone to treat patients with multiple myeloma showed an increased risk of death.
Sleep and rest are two different concepts. Society focuses on sleep, but rest is just as important, and not just for the physical body. Rest allows us to nurture our physical, mental, emotional, sensory, creative, social, and spiritual self. Each of those dimensions needs to be consciously rested for a person to truly feel restored.
Scientists created a new cancer immunotherapy approach that uses a new type of CAR T cells to stimulate an immune response against cells that are missing one gene copy. They reported their findings in Proceedings of the National Academy of Sciences.
On July 26, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and continued as a single agent as adjuvant treatment after surgery.